Mastalgia medical therapy

Revision as of 22:38, 29 July 2020 by WikiBot (talk | contribs) (Bot: Removing from Primary care)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mastalgia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mastalgia from other Conditions

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mastalgia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mastalgia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mastalgia medical therapy

CDC on Mastalgia medical therapy

Mastalgia medical therapy in the news

Blogs on Mastalgia medical therapy

Directions to Hospitals Treating Mastalgia

Risk calculators and risk factors for Mastalgia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Medical Therapy

Acute Pharmacotherapies

Symptomatic treatment includes:

  • Indicated for severe pain or pain lasting > a few days each month
  • Analgesia: acetaminophen or NSAIDs (nonsteriodal anti-inflammatory drugs)
  • Premenstrual engorgement: thiazide diuretic for several days during premenstrual symptoms
  • Other potentially beneficial treatments
  • Avoidance of caffeine: no efficacy in randomized controlled trials (RCTs), but some patients report relief
  • Vitamin E: 400 IU bid beneficial in some studies but not others (2 negative RCTs)
  • Primrose oil (linoleic acid): 1.5-3 g qd effective in 40-60%; may take 3 months for results
  • Danazol
    • Only FDA approved therapy for breast pain
    • Inhibits luteinizing hormone/follicle stimulating hormone (LH/FSH) secretion (decreased exocrine secretion); blocks exocrine effects on breast
    • 100-200 mg qd reduces pain and nodularity in patients with fibrocystic disease
    • Response rate 50-75% for both cyclic and noncyclic breast pain
    • Significant side effects in 20% (weight gain, acne, irregular menses, hirsutism)
  • Tamoxifen: 10 mg bid reduces pain in ~70% via antiestrogen effect
  • Bromocriptine: 1.25-5 mg qd may reduce pain via inhibition of prolactin secretion; +/- data
  • Oral contraceptive pills (OCPs) can reduce fibrocystic changes via progestin component; efficacy for pain uncertain
  • Reduction in hormone replacement therapy (HRT) dose for postmenopausal women, lower E dose may reduce pain

Treatments for cyclical breast pain

Specific treatment for cyclical breast pain will be determined by physician based on:[1]

  • Overall health and medical history
  • Extent of the condition
  • Tolerance for specific medications, procedures, or therapies
  • Expectations for the course of the condition

Treatments vary significantly and may include the following:[2]

  • Caffeine avoidance
  • A low-fat diet
  • Evening primrose oil
  • Vitamin E
  • Any over-the-counter pain-reliever

Various supplemental hormones and hormone blockers are also prescribed. These may include:

Supplemental hormones and hormone blockers may have side effects. In addition, the risks and benefits of such treatment should be carefully discussed.

Treatments for non-cyclical breast pain

Determining the appropriate treatment for noncyclical breast pain is more difficult, not only because it is hard to pinpoint where the pain is coming from, but also because the pain is not hormonal. Depending on the cause, treatment may include analgesics, anti-inflammatory drugs, and compresses.

Reassurance

  • Pain resolves spontaneously in 60-80% and will not require further therapy in 90% of patients
  • Pain, fibrocystic changes, and simple fibroadenomas pose no increase in breast cancer risk
  • Pendulous breasts: soft bra with adequate support

Referral

  • Abnormal findings on exam, mammogram or ultrasound
  • Persistent pain unresponsive to symptomatic treatment

References